Doctors may be able to identify which HER2-negative breast cancer patients will respond to treatment and which patients should switch to an alternative treatment.
Your search for bevacizumab returned 10 results
Ophthalmic injections of bevacizumab exhibited no greater risk of endophthalmitis than injections of ranibizumab, according to a new study published in JAMA Ophthalmology.
Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
The conversion from provisional to full approval was based on totality of evidence of Avastin in glioblastoma.
Data from a Phase 1/2 study in patients with MDS who had disease progression on or after first-line azacitidine treatment showed initial signs of clinical activity with DSP-7888, and that it was well tolerated in study patients.
Genentech announced that the Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin alone, for the treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A recent article published in the journal American Family Physician discusses the important role family physicians play in helping to identify vision loss in older patients.
Treatment with Eylea (aflibercept; Regeneron) led to greater average visual improvement than Avastin (bevacizumab; Genentech) or Lucentis (ranibizumab; Genentech) when vision was 20/50 or worse at treatment initiation, but similar improvement when the starting vision was 20/40-20/32, data from a clinical trial has shown.
Amgen announced new data from its PEAK and PRIME studies that support Vectibix (panitumumab), in combination with FOLFOX, as first-line therapy in patients with wild-type RAS metastatic colorectal cancer (mCRC)